The company’s lead antibiotic programs SLP0904 and SLP0905 derived from chemical scaffolds of marine origin and have been developed to successfully treat infections caused by multi-drug resistant Gram positive pathogens e.g. VRE, MRSA, strains resistant to Mupirocin (antibiotic) and other broad spectrum antibiotics.
Systemic new class anti-Gram positive small molecule (iv and/or oral) at pre-clinical development stage.
Topical new class small molecule anti-Gram positive; ready for Phase I.
Pipeline activities in Gram-negative infections have led to:
Antimicrobial polymeric compound in pre-clinical stage against Gram-positive/Gram-negative bacteria,
fungi and virus which has its origin in copying coral defense strategies.
Please find the current Sealife development programm on the right and click on it for a bigger view!